MERCK has welcomed the TGA approval for updated indication, dosing and safety information for Mavenclad (cladribine) tablets for the treatment of relapsing-remitting multiple sclerosis.
The changes include a new name for the product, which is a short course oral therapy to reduce the frequency of MS relapses.
The above article was sent to subscribers in Pharmacy Daily's issue from 08 Dec 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Dec 17
